Cervical Cancer Clinical Trials 2024

Cervical Cancer Clinical Trials 2024

Cervical Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in cervical cancer clinical trials today.

Cervical Cancer Clinical Trials

Here are the 6 most popular medical studies for cervical cancer

Popular filter options for cervical cancer trials

Endometrial Cancer Clinical Trials

View 11 Endometrial Cancer medical studies.

Ductal Carcinoma Clinical Trials

View 11 Ductal Carcinoma medical studies.

Metastatic Cervical Cancer Clinical Trials

View 97 metastatic cervical cancer medical studies.

Phase 3 Cervical Cancer Clinical Trials

View 97 phase 3 cervical cancer medical studies.

Cervical Cancer Clinical Trials With No Placebo

View 97 cervical cancer medical studies that do not have a placebo group.

View More Cervical Cancer Trials

See another 70 medical studies focused on cervical cancer.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to cervical cancer

What are the top hospitals conducting cervical cancer research?

Cervical cancer, a condition that affects thousands of women each year, has prompted top hospitals across the United States to conduct innovative clinical trials. Leading the charge is Houston's M D Anderson Cancer Center, with eight ongoing trials dedicated to cervical cancer and an impressive 30 completed studies since their maiden trial in 2005. Meanwhile, at the University of Virginia in Charlottesville, researchers are actively engaged in five clinical trials for cervical cancer treatment. Their commitment to finding new solutions began back in 2001 when they initiated their first recorded trial on this disease.

Notably, Memorial Sloan Kettering Cancer Center in New york City has been making significant contributions as well. With four ongoing cervical cancer trials and a notable history of conducting 15 previous investigations since their inaugural trial back in 1994. Another institution committed to advancing knowledge about cervical cancer is the University of Alabama at Birmingham Cancer Center; they have four active clinical trials currently underway and have already conducted seven previous studies after starting their pioneering investigation on this disease ten years ago (in 2009). Last but not least, we find the University of Oklahoma Health Sciences Center located in Oklahoma City - contributing significantly towards our understanding and treatment options regarding cervical carcinoma through its current participation involving four active clinical tests while having contributed twenty-three different experiments which can be traced back nearly thirty years (their earliest recorded trial being held way back until1992).

These esteemed hospitals showcase dedication and collaboration within the medical community as they join forces to combat cervical cancer. Each study brings us one step closer toward improved prevention methods, more effective treatments, and ultimately higher survival rates for those affected by this potentially devastating condition.

Which are the best cities for cervical cancer clinical trials?

When it comes to cervical cancer clinical trials, several cities emerge as key players in advancing research and treatment options. Houston, Texas leads the pack with 28 active trials investigating treatments like Sentinel Lymph Node Biopsy, Cemiplimab, Pembrolizumab/Vibostolimab Co-Formulation, among others. Anchorage, Alaska closely follows with 27 ongoing studies examining interventions such as Nivolumab, Cisplatin, Subprotocol C2 (MET exon 14 deletion/mutation), and more. Toronto, Ontario is also notable with 15 active trials exploring Pembrolizumab/Vibostolimab Co-Formulation and ASTX660 alongside other potential breakthroughs. These cities offer individuals battling cervical cancer access to innovative clinical trials that pave the way for advancements in care and hope for improved outcomes.

Which are the top treatments for cervical cancer being explored in clinical trials?

Clinical trials are paving the way for advancements in cervical cancer treatment, with several promising options currently under exploration. These top treatments include:

  • Pembrolizumab: A breakthrough drug, listed in 2016, that has attracted significant attention with its involvement in three active clinical trials and a total of 14 all-time trials dedicated to cervical cancer.

  • Cisplatin: This well-established treatment option, first listed back in 2001, continues to shine with its participation in three ongoing trials and an impressive history of 74 all-time clinical trials focused on combating cervical cancer.

  • Quality-of-Life Assessment: Recognizing the importance of holistic care, quality-of-life assessments have become integral components of cervical cancer research. With three active trials and a cumulative count of 15 all-time studies since their introduction in 2007.

  • KK-LC-1 TCR-T cells: A newcomer to the scene but showing potential promise. First introduced this year (2022), it is currently being investigated through one active trial as part of innovative efforts to revolutionize cervical cancer treatment.

With each study bringing us closer to improved outcomes for patients battling this disease, these top treatments offer hope for a brighter future against cervical cancer.

What are the most recent clinical trials for cervical cancer?

Exciting advancements are underway in the field of cervical cancer research, with recent clinical trials offering promising prospects for patients. Among these trials is Arm B, which investigates a combination of clinic-based and at-home treatments for cervical cancer. Additionally, NPX267 has shown potential as a treatment option in Phase 1 trials for this challenging disease. Sacituzumab Govitecan also holds promise based on its positive outcomes observed in Phase 2 studies. Furthermore, CTX131 has entered both Phase 1 and Phase 2 to evaluate its efficacy against cervical cancer. Lastly, E7 TCR-T cells have demonstrated encouraging results in Phase 2 investigations as a potential therapeutic approach. These ongoing efforts bring hope to those affected by cervical cancer and mark significant progress towards better treatment options.

What cervical cancer clinical trials were recently completed?

In recent years, a multitude of clinical trials have been completed in the pursuit of advancements against cervical cancer. Noteworthy among these is the successful completion in October 2020 of a trial exploring NKTR-255, led by Nektar Therapeutics. Another significant milestone was achieved through an investigation into Bevacizumab sponsored by EMD Serono Research & Development Institute, Inc., also completed in October 2020. Furthermore, AK104 underwent testing with sponsorship from Akeso and concluded its trial in July 2020. These achievements represent vital steps forward as researchers persistently strive to improve treatments for cervical cancer patients.